Heron Therapeutics jumps on favorable court ruling over Cinvanti patents

Heron Therapeutics

04/12/2024 11:43

** Shares of drugmaker Heron Therapeutics  HRTX.O  rise
86.4% to $2.20 premarket
    ** On Tuesday, HRTX said a U.S. district court ruled in
favor of co in patent lawsuit against Fresenius Kabi USA
    ** Court validates HRTX's Cinvanti patents until 2035,
blocking Fresenius from making a generic version, co said
    ** Cinvanti is a medication used to prevent nausea and
vomiting caused by chemotherapy
    ** Fresenius Kabi did not immediately respond to a Reuters
request for comment
    ** As of last close, stock had fallen 30.6% YTD

 (Reporting by Kamal Choudhury in Bengaluru)
 ((Kamal.Choudhury@thomsonreuters.com;))